The Wilms' tumour-suppressor gene (WT1), encodes a zinc-finger transcription factor that is critical for the development of several organs, including the kidneys, gonads and spleen. Despite its identification as a tumour suppressor that plays a crucial role in the formation of a paediatric malignancy of the kidneys (Wilms' tumour), it has also emerged as an oncogenic factor influencing proliferation and apoptosis in a large variety of adult cancers. This review focuses on new insights into WT1's role in early development and its potential oncogenic role in adult cancer.
Introduction
The WT1 gene was originally identified as a tumour suppressor involved in the formation of Wilms' tumour of the kidney, and was additionally found to be associated with genitourinary disorders such as Denys Drash and Frasier syndromes (reviewed in [1] [2] [3] ). It encodes a protein with four C-terminal zinc-fingers which can act as a transcriptional regulator or RNA processing factor (reviewed in [4] ). These different functions are partly achieved through a combination of alternative splicing, use of alternative start codons and RNA editing which can potentially lead to the production of 24 isoforms.
One alternative splice event (KTS+) inserts a three amino acid sequence (Lys-Thr-Ser) between zinc fingers 3 and 4, and the other alternative splice (+17AA) inserts 17 amino acids Nterminal to the zinc fingers. Whereas WT1 isoforms lacking the KTS sequence (KTS−) bind DNA with high affinity and function in transcriptional regulation, KTS+ isoforms have a high affinity for RNA and function in RNA metabolism and possibly splicing. Recently, a potential oncogenic role for WT1 has been described in a variety of tumours from different origins and tumour-derived cell lines. In the present review, we focus on recent advances in our understanding of WT1's role in development and tumour formation.
WT1 in early development
Wt1-knockout mice die at an early stage of embryonic development, probably as a result of heart and diaphragm malformations. In addition, they lack kidneys, gonads and adrenal glands [5] , and have defects in the formation of the spleen [6] , retinas [7] and liver [8] . Strikingly, many organs in the knockouts show increased apoptosis including the kidney, gonads, spleen and retina; however, the underlying mechanisms remain to be elucidated.
To study WT1's role in later stages of development, advanced transgenic techniques, such as cre-lox and RNAi (RNA interference), have been applied. Absence of WT1 from knockout mice severely impairs development of the kidneys due to failure of ureteric bud invasion and extensive apoptosis of the metanephric mesenchyme [5] . Knocking down WT1 with siRNA (small interfering RNA) at early stages of kidney development in three-dimensional organ culture blocks the development of the ureteric bud, increases apoptosis and thus mimics the phenotype of the Wt1-knockout mouse. However, repression of WT1 expression at later stages of development prevents cells from differentiating into nephrons, and causes them to proliferate abnormally, thus potentially representing those cells that give rise to Wilms' tumours in humans [9] .
Mouse models with targeted inactivation of either +KTS or −KTS splice variants die soon after birth, but show that both isoforms have overlapping, but also clearly distinct, functions in kidney development and gonad formation. Animals lacking WT1 (−KTS) have a reduced kidney and gonad size, which indicates that this splice variant is crucial for the survival of embryonic tissue. Mice lacking WT1 (+KTS) show a complete XY sex reversal due to a reduction in Sry (sex-determining region Y) expression levels [10] . This is similar to the phenotype of Frasier syndrome patients who have reduced WT1 (+KTS) levels due to mutations in this splice donor site. Further analysis of WT1's role in gonadal development using a conditional knockout showed that WT1 is required for expression of the testis-determining gene Sox9 and maintenance of the tubular architecture in testicular development [11] . Additionally, WT1 activates Amhr2 (anti-Muellerian hormone type II receptor), thereby regulating Muellerian duct regression [12] . Interestingly, stabilization of β-catenin and WT1 ablation causes similar phenotypes in Sertoli cells, and Chang et al. [13] have demonstrated that WT1 negatively regulates β-catenin signalling and have shown that this is essential for testis development.
WT1, a candidate oncogene
WT1 expression in the adult kidney appears to be limited to the podocytes and, although functioning as a tumour suppressor in the formation of Wilms' tumour, it is becoming increasingly clear that WT1 is expressed in a variety of adult tumours from various origins where it is not normally expressed, including carcinomas of the lung [14] , colon [15] and pancreas [16] , as well as breast [17] , desmoid [18] and brain tumours [19] . Since no mutations have been identified in the WT1 gene, it has been suggested that WT1 might function as an oncogene in these tumours (reviewed in [20] ).
In support of this, Tuna et al. [21] demonstrated that WT1 is required for proliferation and inhibition of apoptosis in breast cancer cells using antisense oligonucleotides. Additionally, down-regulation of WT1 was associated with decreased Bcl-2 and cyclin D1 mRNA and protein levels [21] . The bcl-2 gene has previously been identified as a direct target of WT1, but its regulation is highly context-specific. Stable overexpression of WT1 led to an increase of endogenous Bcl-2 protein in the rhabdoid tumour cell line G401 [22] , whereas others have shown that WT1 negatively regulates the bcl-2 promoter in a prostate cancer cell line [23] . The nature of these differences is not known, but it is tempting to speculate that recently identified transcriptional WT1 co-factors, such as BASP1 (brain acid-soluble protein 1) [24, 25] and WTIP (WT1-interacting protein) [26] , might be responsible for some of these differences in WT1-mediated transcriptional regulation of target genes such as bcl-2.
The strongest evidence for an oncogenic role of WT1 comes from studies in leukaemias where WT1 overexpression was first reported by Miwa et al. [27] . Those early findings have now been confirmed by numerous studies reporting increased WT1 expression in AML (acute myeloid leukaemia) [28] , in CML (chronic myeloid leukaemia), ALL (acute lymphoblastic leukaemia) and MDS (myelodysplastic syndrome) (reviewed in [29] ). Consistent with an oncogenic role of WT1, high WT1 levels are associated with poor prognosis [30, 31] . Indeed, knockdown of endogenous WT1 in AML cell lines and primary AML samples decreases growth and causes rapid induction of apoptosis [32, 33] .
Among the several studies that report an anti-apoptotic function for WT1, the +17AA form has been found to have a more potent effect [22, [33] [34] [35] . Interestingly, mice lacking the +17AA isoform of WT1 do not show any abnormalities, which has led to the proposal that this form of WT1 might play an important role in the disease process rather than in development. Indeed, several tumours in which WT1 is expressed show an excess of the +17AA form of WT1, and specifically targeting this isoform has been proposed as a potential therapeutic [33, 35, 36] .
WT1 is also expressed in a large variety of tumour blood vessels and is transcriptionally up-regulated under conditions of reduced oxygen supply, as found in the core of tumours, by HIF (hypoxia-inducible factor)-1 [37] . Furthermore, WT1 is involved in endothelial cell proliferation, vascular formation and migration, indicating that it might be a general marker for angiogenesis [38] . The fact that oncogenic WT1 expression seems to be tumour-specific makes it a good target for therapeutic intervention. Promising results were achieved in trials using peptide vaccines against WT1 in patients with leukaemia, breast and lung cancer, which resulted in tumour regression without damage to normal tissue [39] . However, future studies are needed to clearly define WT1's role in tumorigenesis.
